{"nctId":"NCT00943111","briefTitle":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)","startDateStruct":{"date":"2009-09"},"conditions":["Gaucher Disease, Type 1"],"count":160,"armGroups":[{"label":"Investigational","type":"EXPERIMENTAL","interventionNames":["Drug: Eliglustat tartrate"]},{"label":"Imiglucerase","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Imiglucerase"]}],"interventions":[{"name":"Eliglustat tartrate","otherNames":["Genz-112638"]},{"name":"Imiglucerase","otherNames":["CerezymeÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The participant (and/or their parent/legal guardian) was willing and able to provide signed informed consent prior to any study-related procedures to be performed\n* The participant was at least 18 years old at the time of randomization\n* The participant had a confirmed diagnosis of Gaucher disease type 1\n* The participant had received treatment with ERT for at least 3 years. Within the 9 months prior to randomization, the participant had received a total monthly dose of 30 to 130 Units/kilogram for at least 6 months\n* The participant had reached Gaucher disease therapeutic goals prior to randomization\n* Female participants of childbearing potential must have had a documented negative pregnancy test prior to dosing. In addition, all female participants of childbearing potential must use a medically accepted form of contraception throughout the study\n\nExclusion Criteria:\n\n* The participant had a partial or total splenectomy within 3 years prior to randomization\n* The participant had received substrate reduction therapies for Gaucher disease within 6 months prior to randomization\n* The participant had Gaucher disease type 2 or 3 or was suspected of having Gaucher disease type 3\n* The participant had any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal (GI), pulmonary, neurologic, endocrine, metabolic (e.g. hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may confound the study results or, in the opinion of the Investigator, may preclude participation in the study\n* The participant had tested positive for the human immunodeficiency virus (HIV) antibody, Hepatitis C antibody, or Hepatitis B surface antigen\n* The participant had received an investigational product within 30 days prior to randomization\n* The participant was pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Remained Stable for 52 Weeks During the Primary Analysis Period","description":"For a participant to be classified as stable, the participant must have remained stable in hematological parameters (hemoglobin levels and platelet counts) and organ volumes (spleen, when applicable, and liver volumes in multiples of normal \\[MN\\]). Stable hematological parameters were defined as hemoglobin level did not decrease more than (\\>) 1.5 gram per deciliter (g/dL) from baseline and platelet count did not decrease \\>25% from baseline. Stable organ volumes were defined as spleen volume (in MN) did not increase \\>25% from baseline, if applicable, and liver volume (in MN) did not increase \\>20% from baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.8","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Remained Stable Annually for 4 Years During the LTTP","description":"For a participant to be classified as stable, the participant must have remained stable in hematological parameters (hemoglobin levels and platelet counts) and organ volumes (spleen, when applicable, and liver volumes in MN). Stable hematological parameters were defined as hemoglobin level did not decrease \\>1.5 g/dL from baseline and platelet count did not decrease \\>25% from baseline. Stable organ volumes were defined as spleen volume (in MN) did not increase \\>25% from baseline, if applicable, and liver volume did not increase \\>20% from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Total T-Scores for Bone Mineral Density","description":"Images of the spine and bilateral femur were obtained by dual energy X-Ray absorptiometry (DXA) to determine T-score for each bone area and total bone mineral density. T-score compares participant's bone density with that of healthy young participant. The T-score bone density categories are: normal (score greater than \\[\\>\\]-1), osteopenia (score -2.5 to less than or equal to \\[\\<=\\] -1), and osteoporosis (score \\<= -2.5).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"1.309"},{"groupId":"OG001","value":"-0.33","spread":"1.169"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"1.080"},{"groupId":"OG001","value":"-0.47","spread":"1.293"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total T-Scores for Bone Mineral Density at Week 52","description":"Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. T-score compares participant's bone density with that of healthy young participant. The T-score bone density categories are: normal (score \\>-1), osteopenia (score -2.5 to \\<=-1), and osteoporosis (score \\<= -2.5). Absolute change = T-score at Week 52 minus T-score at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.03"},{"groupId":"OG001","value":"0.03","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.02"},{"groupId":"OG001","value":"-0.03","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Total Z-Scores for Bone Mineral Density","description":"Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score \\>-2) and below normal (score \\<=-2).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"1.260"},{"groupId":"OG001","value":"-0.14","spread":"1.108"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"1.020"},{"groupId":"OG001","value":"-0.18","spread":"1.122"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total Z-Scores for Bone Mineral Density at Week 52","description":"Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score \\>-2) and below normal (score \\<=-2). Absolute change = Z-score at Week 52 minus Z-score at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.03"},{"groupId":"OG001","value":"0.06","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.02"},{"groupId":"OG001","value":"0.02","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Hemoglobin Level","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.592","spread":"1.2467"},{"groupId":"OG001","value":"13.797","spread":"1.2234"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Hemoglobin Levels at Week 52","description":"Absolute change = hemoglobin level at Week 52 minus hemoglobin level at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.07"},{"groupId":"OG001","value":"0.05","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Platelet Counts at Week 52","description":"Percent change in platelet counts = (\\[platelet count at Week 52 minus platelet count at baseline\\] divided by \\[platelet count at baseline\\]) multiplied by 100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":"1.71"},{"groupId":"OG001","value":"2.63","spread":"2.47"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Spleen Volume (MN) at Week 52","description":"Percent change in spleen volume = (\\[spleen volume at Week 52 minus spleen volume at baseline\\] divided by \\[spleen volume at baseline\\]) multiplied by 100, where all volumes are in MN.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.05","spread":"1.57"},{"groupId":"OG001","value":"-3.22","spread":"2.13"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Liver Volume (in MN) at Week 52","description":"Percent change in liver volume = (\\[liver volume at Week 52 minus liver volume at baseline\\] divided by \\[liver volume at baseline\\]) multiplied by 100, where all volumes are in multiples of normal.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.94"},{"groupId":"OG001","value":"3.13","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total T-Scores for Bone Mineral Density at Week 208","description":"Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. T-score compares participant's bone density with that of healthy young participant. The T-score bone density categories are: normal (score \\>-1), osteopenia (score -2.5 to \\<=-1), and osteoporosis (score \\<= -2.5). Absolute change = T-score at Week 208 minus T-score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.405"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.345"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Total Z-Scores for Bone Mineral Density at Week 208","description":"Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score \\>-2) and below normal (score \\<=-2). Absolute change = Z-score at Week 208 minus Z-score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.358"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.381"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Hemoglobin Levels at Week 208","description":"Absolute change = hemoglobin level at Week 208 minus hemoglobin level at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.297","spread":"0.7472"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Platelet Counts at Week 208","description":"Percent change in platelet counts = (\\[platelet count at Week 208 minus platelet count at baseline\\] divided by \\[platelet count at baseline\\]) multiplied by 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.990","spread":"20.4382"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Spleen Volume (in MN) at Week 208","description":"Percent change in spleen volume = (\\[spleen volume at Week 208 minus spleen volume at baseline\\] divided by \\[spleen volume at baseline\\]) multiplied by 100, where all volumes are in MN.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.768","spread":"17.9435"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Liver Volume (in MN) at Week 208","description":"Percent change in liver volume = (\\[liver volume at Week 208 minus liver volume at baseline\\] divided by \\[liver volume at baseline\\]) multiplied by 100, where all volumes are in multiples of normal.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.345","spread":"12.8795"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":106},"commonTop":["Arthralgia","Nasopharyngitis","Headache","Abdominal pain upper","Back pain"]}}}